3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
221
Polycystic Ovary Syndrome
36
Endometrial Neoplasms
15
Ovarian Neoplasms
13
Infertility
11
Neoplasm Metastasis
9
Carcinoma, Intraductal, Noninfiltrating
7
Fallopian Tube Neoplasms
6
Neoplasms
5
Breast Diseases
5
Triple Negative Breast Neoplasms
4
Osteoporosis
4
Leiomyoma
4
Infertility, Female
4
Breast Neoplasms, Male
4
Breast Carcinoma In Situ
4
Arthralgia
4
Advanced Breast Cancer
4
Recurrence
3
Obesity
3
Breast Cancer Metastatic
3
Anovulation
3
Uterine Neoplasms
2
Solid Tumor
2
Prostatic Neoplasms
2
Progesterone Resistance
2
Pancreatic Neoplasms
2
Pain
2
Leiomyosarcoma
2
HR Positive HER2 Negative Advanced Breast Cancer
2
Interventions
Paclitaxel
7
Doxorubicin
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
Bevacizumab
4
durvalumab
3
Radiotherapy
3
Propranolol
3
Docetaxel
3
regorafenib
2
cemiplimab
2
Surveys and Questionnaires
2
Sunitinib
2
Standard of Care
2
Nivolumab
2
Ifosfamide
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trebananib
1
trastuzumab duocarmazine
1
talimogene laherparepvec
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hemangiosarcoma
×
Letrozole
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled